Original Article IL-17 expression in synovial fluid and synovial membrane in patients with knee osteoarthritis

Similar documents
Concentrations of serum cartilage oligomeric matrix protein after anterior cruciate ligament injury.

Priorities Forum Statement GUIDANCE

Study on the clinical value of mirna98b as a potential biomarker for osteoarthritis.

Evaluation and Treatment of Knee Arthritis Classification of Knee Arthritis Osteoarthritis Osteoarthritis Osteoarthritis of Knee

Medial Knee Osteoarthritis Precedes Medial Meniscal Posterior Root Tear with an Event of Painful Popping

Osteoarthritis. Dr Anthony Feher. With special thanks to Dr. Tim Williams and Dr. Bhatia for allowing me to use some of their slides

QUANTITATIVE DETERMINATION OF HUMAN CARTILAGE OLIGOMERIC MATRIX PROTEIN (COMP) ELISA

Mitsuru Hanada 1, Masaaki Takahashi 2, Hiroki Furuhashi 1, Hiroshi Koyama 1 and Yukihiro Matsuyama 1. Research Article

Osteoarthritis. RA Hughes

4 2 Osteoarthritis 1

Types of osteoarthritis

Rheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011

A. Kopchev, S.Monov, D. Kyurkchiev, I.Ivanova, T. Georgiev (UMHAT St. Ivan Rilski, Medical University - Sofia, Bulgaria)

IV2-113E Use by. Invitron Glargine ELISA Kit REF LOT IVD. Definitions. English. For in-vitro diagnostic use. Instructions for use.

A Comparative Study of Ultrasonographic Findings with Clinical and Radiological Findings of Painful Osteoarthritis of the Knee Joint

Mouse HBsAg(Hepatitis B Virus Surface Antigen) ELISA Kit

Arthroscopy. Turnberg Building Orthopaedics

Osteoarthritis What is new? Dr Peter Cheung, Rheumatologist, NUHS

Prof. FABIO CERZA A.Carcangiu, S.Carnì, A. Pecora, I. Di Vavo, V. Schiavilla

What is the most effective MRI specific findings for lateral meniscus posterior root tear in ACL injuries

Insulin (Porcine/Canine) ELISA

Rehab Considerations: Meniscus

Arthritis & Rheumatism

Intraosseous Bio Filler. Surgical Technique

NBQX, An AMPA/Kainate Glutamate Receptor Antagonist, Alleviates Joint Disease In Models Of Inflammatory- And Osteo- Arthritis.

In the Treatment of Patients With Knee Joint Osteoarthritis, Are Platelet Rich Plasma Injections More Effective Than Hyaluronic Acid Injections?

TSH Receptor Autoantibody ELISA

Discovery of a Small Molecule Inhibitor of the Wnt Pathway as a Potential Disease Modifying Treatment for Knee Osteoarthritis

colorimetric sandwich ELISA kit datasheet

Nanomechanical Symptoms in Cartilage Precede Histological Osteoarthritis Signs after the Destabilization of Medial Meniscus in Mice

Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04690) as a Potential Disease Modifying Treatment for Knee Osteoarthritis

Patient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour

Rat Insulin ELISA. For the quantitative determination of insulin in rat serum and plasma. For Research Use Only. Not For Use In Diagnostic Procedures.

International Cartilage Repair Society

Live On Screen: Knee Injections ABCs of Musculoskeletal Care. Knee aspiration. Objectives. I have no disclosures.

IL-17 in primary knee osteoarthritis and its relation with severity of the disease

Instructions for use. TSH rat ELISA. Please use only the valid version of the Instructions for Use provided with the kit AR E-8600

Human HIV (1+2) antigen&antibody ELISA Kit

Save the meniscus Mais pourquoi?

DIAGNOSTIC AUTOMATION, INC.

See external label 2 C-8 C Σ=96 tests Cat # 3122Z MICROWELL ELISA THYROID STIMULATING HORMONE (TSH) ENZYME IMMUNOASSAY TEST KIT TSH.

Canine Thyroid Stimulating Hormone, TSH ELISA Kit

Key words: arthroscopy, orthopaedic examination, magnetic resonance imaging, knee injury.

Bovine Insulin ELISA

AOS 3: Rheumatoid Arthritis

Rheumatoid Arthritis

Classification of Acetabular Cartilage Lesions. Claudio Mella, MD

Porcine/Canine Insulin ELISA

Rat Leptin ELISA FOR LABORATORY USE ONLY YANAIHARA INSTITUTE INC AWAKURA, FUJINOMIYA - SHI SHIZUOKA, JAPAN

Human TSH ELISA Kit. User Manual

Rat cholesterol ELISA Kit

Human Obestatin ELISA

Association of anti-mcv autoantibodies with SLE (Systemic Lupus Erythematosus) overlapping with various syndromes

Pain in Osteoarthritis

Immunological Aspect of Ozone in Rheumatic Diseases

KNEE INJURIES IN SPORTS MEDICINE

25(OH) Vitamin D ELISA (BD-220BA), 192 Tests

Rat Leptin-HS ELISA FOR LABORATORY USE ONLY YANAIHARA INSTITUTE INC AWAKURA, FUJINOMIYA - SHI SHIZUOKA, JAPAN

LDL (Human) ELISA Kit

EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS

Xingzhong (Jason) Jin

Arthrex ACP Double Syringe. ACP - Autologous Conditioned Plasma

Mouse C-peptide ELISA

Diagnostic and prognostic value of some biochemical markers in early knee osteoarthritis

Rheumatoid Arthritis. Manish Relan, MD FACP RhMSUS Arthritis & Rheumatology Care Center. Jacksonville, FL (904)

Non-Surgical vs. Surgical Treatment of Meniscus Tears of the Knee

Insulin ELISA. For the quantitative determination of insulin in serum and plasma.

Mercodia Porcine C-peptide ELISA

Human Thyroid-Peroxidase Antibody, TPO-Ab ELISA Kit

This kit is intended for Research Use Only. Not for use in diagnostic procedures.

Mouse Leptin ELISA Kit (mleptin-elisa)

UvA-DARE (Digital Academic Repository)

Mouse Adiponectin Immunoassay Kit

Assessment of the role of platelet rich plasma (PRP) in mild to moderate osteoarthritis knee joint using VAS and WOMAC score

Functional and radiological outcome of total knee replacement in varus deformity of the knee

Mouse Ultrasensitive Insulin ELISA

Human HBcAb IgM ELISA kit

BRIEF REPORT. KENNETH D. BRANDT, ROSE S. FIFE, ETHAN M. BRAUNSTEIN, and BARRY KATZ. From the Department of Medicine, the Department of

Ultrasound in Rheumatology

Mouse C3 (Complement Factor 3) ELISA Kit

Human Apolipoprotein A1 EIA Kit

GLUCOSE CONCENTRATION INCREASES IGF EXPRESSION FROM SYNOVIAL MEMBRANE

Platelet rich plasma for the treatment of osteoarthrosis knee

I. Introduction. II. Characteristics

HBeAg and HBeAg Ab ELISA Kit

Synovial Chondromatosis Associated with Polyarteritis Nodosa

ORIGINAL INVESTIGATION. Natural History of Knee Cartilage Defects and Factors Affecting Change

Meniscus T2 Relaxation Time at Various Stages of Knee Joint Degeneration

ab ATP Synthase Enzyme Activity Microplate Assay Kit

CLINICAL ANALYSIS ON ARTHOSCOPIC MENISCAL REPAIR BY FAST-FIX SYSTEM

Clinical Observation of Minimally Invasive Surgery and Conservative Treatment for Ankle Degenerative Osteoarthropathy Bo GOU 1 and Xiao-tao WANG 2, *

Mercodia Glucagon ELISA

An Owner's Guide to Natural Healing. Autologous Conditioned Plasma (ACP)

Case Report Ochronotic arthritis of bilateral knees: a case report

Rat C-peptide ELISA. For the quantitative determination of C-peptide in rat serum

Pigmented Villonodular Synovitis PVNS

Lipid (Oil Red O) staining Kit

Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska

Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis

FOR LABORATORY USE ONLY

Transcription:

Int J Clin Exp Med 2017;10(2):3400-3405 www.ijcem.com /ISSN:1940-5901/IJCEM0044782 Original Article IL-17 expression in synovial fluid and synovial membrane in patients with knee osteoarthritis Guo-Liang Wang 1,2, Wei-Dong Mu 1 1 Department of Traumatic Orthopedics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China; 2 Department of Orthopedics, Weifang No. 2 People s Hospital, Weifang, Shandong, China Received November 21, 2016; Accepted December 25, 2016; Epub February 15, 2017; Published February 28, 2017 Abstract: Objective: In the present study, we aimed to detect the levels of IL-17 in the serum, synovial fluid, and synovial membrane of patients with knee osteoarthritis (KOA) and investigate their association with the severity of articular cartilage damage and synovitis. Methods: According to the American College of Rheumatology criteria for osteoarthritis (OA) diagnosis, 46 cases diagnosed with knee OA (KOA group) were selected from patients that underwent arthroscopic surgery at our hospital from June 2012 to June 2014. Additional 46 cases with other knee joint diseases (non-koa group) were included as controls. The IL-17 levels in synovial fluid and serum were assayed by ELISA, and those in the synovial membrane were assayed by immunohistochemistry. The severity of knee articular cartilage damage and synovitis-related pathological changes was evaluated by arthroscopy using the Outerbridge and Ayral scores, respectively. Results: IL-17 levels in the synovial fluid and synovial membranes of the KOA group were significantly higher than in the non-koa group (P < 0.05). The levels of IL-17 in the synovial fluid and synovial membranes were positively correlated with the serum level of high-sensitivity C-reactive protein (HS-CRP), the Outerbridge score, and the Ayral score in the KOA group. Conclusion: IL-17 levels in the synovial fluid and synovial membrane are increased in KOA patients and are positively correlated with KOA severity. Keywords: Osteoarthritis, IL-17, synovial fluid, synovial membrane Introduction Osteoarthritis (OA) is a chronic joint disease characterized by degeneration, destruction, hyperplasia, and synovitis of the articular cartilage and subchondral bone [1]. Obesity, trauma, age, gender (more common in women), and biochemical factors are the main risk factors for OA [2]. However, the pathogenesis of OA has not been explicitly documented [3]. Magnetic resonance imaging (MRI) and arthroscopy are important methods to evaluate the severity of knee osteoarthritis (KOA). However, these methods have a limited role in KOA diagnosis. Therefore, it is necessary to explore quantitative and sensitive methods for the examination of KOA. In recent years, research has shown that biomarker testing is a potential method for the early diagnosis of KOA. The radiographic grade of KOA is associated with a number of biomarkers in knee synovial membranes, such as P-selectin, cartilage oligomeric matrix protein, proteoglycans, and high-sensitivity C-reactive protein (HS-CRP) [4]. It has been demonstrated that IL-17 might play a crucial role in KOA pathogenesis and is closely related to pain [5]. The accurate and effective regulation of IL-17 signaling can prevent inflammation. In the present study, the IL-17 levels in serum, synovial fluid, and synovial membrane from KOA patients were tested to analyze their association with the severity of knee articular cartilage damage and synovitis-related pathological changes. Materials and methods Patients According to the American College of Rheumatology (ACR) criteria for the diagnosis of KOA, 46 patients diagnosed with OA (KOA group) were selected from patients who underwent arthroscopic surgery at Weifang No. 2 People s Hospital from June 2012 to June 2014. Addi-

The diagnostic criteria for KOA according to the ACR criteria for the diagnosis of KOA include: (1) knee pain for most of the time for a month, (2) snapping joint activities, (3) morning stiffness 30 min, (4) age 40 years, (5) knee joint swelling with snapping, and (6) knee joint swelling without snapping. OA was diagnosed upon the observation of at least the combinations (1), (2), (3) and (4), or (1), (2), (3) and (5), or (1) and (6). The exclusion criteria included other associated inflammatory arthritis or autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus or gout; a history of steroid injections or non-steroidal drug use over the past three months, a history of severe trauma in the knee joint, or associated severe liver and kidney dysfunction and cardiovascular disease. Figure 1. Expression of IL-17 in the synovial membrane. Synovial membrane sections were prepared, and IL-17 expression was examined by immunohistochemistry. The sections were observed under the microscope. Five fields of view at high magnification (400 ) were chosen randomly from each stained section. Table 1. IL-17 levels in the serum and synovial fluid of patients with KOA and non-koa (µg/l) Group Cases Synovial fluid Serum KOA 46 3.94 ± 0.030 1.55 ± 0.02 Non-KOA 46 2.47 ± 0.03 1.11 ± 0.02 T - 2.83 0.026 P - 0.042 0.928 tionally, 46 cases with other knee joint diseases (non-koa group) were included as controls. The KOA group included 22 males and 24 females, ranging in ages from 45-81 years and an average age of 60 years; the mean body mass index was 18.1 to 26.9, and the mean course of disease lasted from 8 to 87 months. The non-koa group included 25 males and 21 females, ranging in ages from 43-80 years and an average age of 58 years; there were 28 cases of meniscus injury and 18 cases of anterior cruciate ligament injury. The study was approved by the ethics committee of our hospital. A signed informed consent form was obtained from all the patients. The inclusion criteria included (1) arthroscopic anterior cruciate ligament reconstruction, and (2) meniscus angioplasty or arthroscopy. Arthroscopic evaluation of articular cartilage damage and synovitis-related pathological changes The severity of articular cartilage damage and synovitis was evaluated in accordance with the findings of knee arthroscopy using the Outerbridge [6] and Ayral scores [7], respectively. Collection and preservation of serum and synovial fluid specimens For the serum specimens, the patients were required to fast for drink eight hours before the operation. Four-milliliter fasting blood specimens were collected through the ulnar vein in the morning. The specimens were placed in sterile tubes without any anticoagulant and centrifuged at 800 g for 15 min. The serum specimens were retained and dispensed into micro-centrifuge tubes immediately. Each tube was labeled and frozen at -80 C. Synovial fluid specimens: After anesthesia, 4-5 ml synovial fluid specimens were extracted by puncturing the knee joint cavity through the lateral supra-patellar approach. The specimens were collected in serum tubes and centrifuged at 3,000 rpm for 15 min within 2 hours of sur- 3401 Int J Clin Exp Med 2017;10(2):3400-3405

Table 2. IL-17 levels in the synovial membrane of patients with KOA and non-koa (µg/l) Group Cases Synovial membrane KOA 46 43.60 ± 6.28 Non-KOA 46 32.22 ± 5.73 T - 3.39 P - 0.02 The sample concentrations of IL-17 were calculated from the standard curve. Serum HS-CRP analysis Serum samples were removed from -70 C storage and were completely thawed to room temperature. The HS-CRP concentration in each sample of the KOA group was assayed by a rate nephelometric immunoassay. Immunohistochemical assay for IL-17 Figure 2. IL-17 levels in the serum and synovial fluid of patients with KOA and non-koa. IL-17 protein expression was examined by ELISA. gery. The supernatants were then collected into micro-centrifuge tubes and stored at -80 C. ELISA for IL-17 in synovial fluid and serum The levels of IL-17 in synovial fluid and serum were assayed by ELISA using a commercial kit (R&D, USA). The blank control, standard, and sample wells were set according to the manufacturer s instructions. The test samples were thawed to room temperature, and 100-μL aliquots of each sample were added into monoclonal antibody-coated 96-well plates. The plates were shaken well, and 50 μl of the affinity substance was added per well, followed by shaking. The reaction solution was incubated at room temperature for 30 min and rinsed repeatedly with a washing solution. Next, 200 μl of TMB color-developing reagent was added to each well and incubated for 15 min. Finally, a termination solution was added at 50 μl per well. The plates were shaken for 5 s to thoroughly mix the substrate and termination solutions. The absorbance of the reaction mixture was measured at 450 nm (A value). Tissue specimens of synovial membrane were collected during arthroscopic surgery. The specimens were washed twice with normal saline within one hour of surgery and then cut into approximately 0.5 cm 0.5 cm 0.5 cm blocks. The tissue blocks were fixed with 10% paraformaldehyde, embedded in paraffin, and sectioned into 4-5 µm-thick slices. The pathology sections were prepared after surgery, and IL-17 expression was assayed by immunohistochemistry. The sections were examined under the microscope. Five fields of view at high magnification (400 ) were chosen randomly from each stained section. One brownish-yellow particle representing a positive result was marked within one of the fields of view and was then used as a standard for automatic detection of all positive results in the field of view. Statistical analysis Statistical analysis was performed with SPSS 18.0. Continuous data were expressed as the mean ± standard deviation (X ± SD). Comparison of means was performed between groups by the t-test. Pearson correlation analysis was conducted on the average integral optical density of various indices. A P value less than 0.05 was considered statistically significant. Results IL-17 expression in the synovial membrane of KOA patients Tissue specimens of the synovial membrane were prepared after surgery, and IL-17 expression was assayed by immunohistochemistry. The specimen sections were examined by microscopy. One brownish-yellow particle representing a positive result was marked within one of the fields of view and was then used as 3402 Int J Clin Exp Med 2017;10(2):3400-3405

Table 3. Correlations between IL-17 levels in the serum, synovial fluid, and synovial membrane and serum HS-CRP concentration in OA patients Group Serum Synovial fluid Synovial membrane IL-17 (µg/l) 1.55 ± 0.03 3.94 ± 0.03 43.6 ± 6.28 HS-CRP (mg/l) 1.91 ± 0.30 1.90 ± 0.30 1.90 ± 0.30 R 0.56 0.87 0.43 P < 0.05 < 0.001 < 0.001 Table 4. Correlations between IL-17 levels in the synovial fluid and synovial membrane and the Outerbridge score of articular cartilage damage in patients with osteoarthritis Synovial membrane Synovial fluid IL-17 (µg/l) 43.6 ± 6.28 1.55 ± 0.03 Outerbridge score 18.71 ± 1.3 18.71 ± 1.3 R 0.68 0.13 P < 0.05 0.007 Next, we evaluated the severity of knee articular cartilage damage and synovitis-related pathological changes by arthroscopy using the Outerbridge and Ayral scores. We found that the IL-17 levels in synovial fluid (1.55 ± 0.03 μg/l) and synovial membrane (43.6 ± 6.28 μg/l) were positively correlated with both the Outerbridge (Table 4) and the Ayral scores (Table 5). These results indicated that as the concentration of IL-17 increased in the synovial tissue, the severity of synovitis correspondingly increased. Discussion were all significantly correlated with serum HS-CRP concentrations (Table 3). IL-17 levels in the synovial fluid and synovial membrane are positively correlated with KOA severity Table 5. Correlations between IL-17 levels in the synovial fluid and synovial membrane and the Ayral score of synovitis in patients with osteoarthritis Synovial membrane Synovial fluid IL-17 (µg/l) 43.6 ± 6.280 1.55 ± 0.03 Ayral score 29.38 ± 0.40 29.38 ± 0.40 R 0.30 0.17 P < 0.05 < 0.05 a standard for automatic detection of all the positive results in the field of view (Figure 1). IL-17 levels were elevated in the synovial fluid and synovial membrane of KOA patients IL-17 levels in the synovial fluid were elevated in patients with KOA compared with the non- KOA group (3.94 ± 0.03 vs. 2.47 ± 0.03 μg/l, P = 0.042). However, in the KOA patients, plasma IL-17 levels were not statistically different from those in the non-koa patients (P > 0.05) (Table 1; Figure 1). As seen from Table 2 and Figure 2, IL-17 levels in the synovial membrane of patients with KOA were significantly increased compared with those in non-koa patients (43.60 ± 6.28 vs. 32.22 ± 5.73 µg/l, P = 0.02). HS-CRP is a sensitive indicator for evaluating KOA. Our results showed that the IL-17 levels in plasma, synovial fluid, and synovial membrane OA is a chronic joint disease characterized by the degeneration, destruction, hyperplasia, and synovitis of the articular cartilage and subchondral bone [8]. Advanced KOA patients often struggle with limited joint mobility, joint deformity, severe pain, and even disability. Ultimately, these patients have to undergo surgical treatment such as joint replacement. KOA patients already undergo significant degeneration of the knee joint prior to the observation of the typical X-ray changes and clinical manifestations [8]. Hence, early diagnosis of KOA is of particular importance. With the rapid development of molecular biology techniques in recent years, scholars have proposed that testing for the associated biomarkers in synovial fluid may be useful for the early diagnosis of KOA [9]. IL-17 might play a crucial role in the pathogenesis of rheumatoid arthritis (RA) [10-13], psoriatic arthritis (PsA) [14], or OA, and is closely related to pain [5]. Previous studies have examined synovial IL-17 levels only in the synovial fluid of OA patients and the control group. The same results have been obtained in our study [5]. However, we showed that the IL-17 levels in the synovial membranes of the KOA group were higher than those in the non-koa group. Statistically significant differences were found between these two groups with respect to the IL-17 levels in the synovial fluid and synovial membrane. 3403 Int J Clin Exp Med 2017;10(2):3400-3405

HS-CRP is secreted by hepatocyte nuclei and adipocytes and is regulated by pro-inflammatory factors. According to existing research, the association between serum HS-CRP and KOA includes the following: (1) HS-CRP is a sensitive indicator for evaluating KOA, (2) HS-CRP is associated with the symptoms of OA patients, including pain and joint function, and (3) HS- CRP has no significant statistical difference with the Kellgren-Lawrence score or the degree of joint space narrowing [15, 16]. The results of the present study showed that the serum HS-CRP level was significantly correlated with the IL-17 levels in the serum, synovial fluid, and the synovial membrane. Previous research has indicated that CRP is closely associated with KOA severity. A recent study also showed that serum CRP levels in KOA are higher in KL4 patients than in KL2 and KL3 patients. Moreover, our results showed that the IL-17 levels in the serum and synovial membrane were correlated with the CRP level. Similar results have also been reported in literature. In this study, IL-17 levels in the synovial fluid and synovial membrane were positively correlated with the Ayral score of synovitis. This correlation was higher between the synovial membrane level of IL-17 and the Ayral score, i.e. as the IL-17 concentration in the synovial membrane increased; the severity of synovitis was correspondingly increased, as was the Ayral score. This result indicates that the level of IL-17 reflects the severity of synovitis. The results from the present study also showed that IL-17 levels in both the synovial fluid and the synovial membrane were positively correlated with the Outerbridge score of cartilage damage. This correlation was higher between the IL-17 concentration in the synovial membrane and the score of the articular cartilage damage, i.e., as IL-17 concentration increased, the severity of the articular cartilage damage increased correspondingly, as did the Outerbridge score. This indicates that IL-17 concentration reflects the severity of articular cartilage damage. KOA is pathologically manifested as synovitis and differing degrees of articular cartilage damage. Arthroscopic evaluation by the Ayral and Outerbridge scores could objectively reflect the severity of KOA. In the present study, IL-17 levels in the serum, synovial fluid, and synovial membrane were determined in KOA patients, and were found to be positively correlated with the Ayral and Outerbridge scores. Therefore, we conclude that the IL-17 levels in the synovial fluid or membrane reflect the severity of synovitis in KOA to some extent, and infer that IL-17 might be another valuable biomarker to reflect KOA severity. Disclosure of conflict of interest None. Address correspondence to: Dr. Wei-Dong Mu, Department of Traumatic Orthopedics, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jin Wu Wei Seventh Road, Jinan 250021, Shandong, China. Tel: 86-531-87938911; Fax: 86-531- 87938911; E-mail: muweidongsd@sina.com References [1] Rahmati M, Mobasheri A, Mozafari M. Inflammatory mediators in osteoarthritis: a critical review of the state-of-the-art, current prospects, and future challenges. Bone 2016; 85: 81-90. [2] Bastick AN, Runhaar J, Belo JN, Bierma- Zeinstra SM. Prognostic factors for progression of clinical osteoarthritis of the knee: a systematic review of observational studies. Arthritis Res Ther 2015; 17: 152. [3] Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol 2016; 12: 412-20. [4] Cheng T, Li FF, Zhao S, Peng XC, Zhang XL. Soluble P selectin in synovial fluid level is correlated with the radiographic severity of knee osteoarthritis. Clin Chim Acta 2010; 411: 1529-1531. [5] Liu Y, Peng H, Meng Z, Wei M. Correlation of IL-17 level in synovia and severity of knee osteoarthritis. Med Sci Monit 2015; 21: 1732-1736. [6] Ayral X, Pickering EH, Woodworth TG, Mackillop N, Dougados M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis--results of a 1-year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 2005; 13: 361-367. [7] Outerbridge RE. The etiology of chondromalacia patellae. J Bone Joint Surg Br 1961; 43: 752-757. [8] Hayashi D, Roemer FW, Guermazi A. Imaging for osteoarthritis. Ann Phys Rehabil Med 2016; 59: 161-169. [9] Madry H, Kon E, Condello V, Peretti GM, Steinwachs M, Seil R, Berruto M, Engebretsen 3404 Int J Clin Exp Med 2017;10(2):3400-3405

L, Filardo G, Angele P. Early osteoarthritis of the knee. Knee Surg Sports Traumatol Arthrosc 2016; 24: 1753-1762. [10] van Baarsen LG, Lebre MC, van der Coelen D, Aarrass S, Tang MW, Ramwadhdoebe TH, Gerlag DM, Tak PP. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti- IL-17 therapy? Arthritis Res Ther 2014; 16: 426. [11] Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P. Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol 2009; 182: 3112-3120. [12] Hot A, Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis 2011; 70: 727-732. [13] van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 549-553. [14] Raychaudhuri SK, Saxena A, Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol 2015; 34: 1019-1023. [15] Jin X, Beguerie JR, Zhang W, Blizzard L, Otahal P, Jones G, Ding C. Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 703-710. [16] Shimura Y, Kurosawa H, Sugawara Y, Tsuchiya M, Sawa M, Kaneko H, Futami I, Liu L, Sadatsuki R, Hada S, Iwase Y, Kaneko K, Ishijima M. The factors associated with pain severity in patients with knee osteoarthritis vary according to the radiographic disease severity: a cross-sectional study. Osteoarthritis Cartilage 2013; 21: 1179-1184. 3405 Int J Clin Exp Med 2017;10(2):3400-3405